05th May 2020

Consilium Strategic Communications advises BerGenBio on over-subscribed €45.4 Million private placement


London, 5 May 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised its client, BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, on the international communication of its €45.4 million private placement.

This successful private placement follows the launch of the UK government-funded ACCORD study, where BerGenBio's lead drug bemcentinib was announced as the first candidate to be fast-tracked for treating the most vulnerable patients with COVID-19. Consilium advised BerGenBio on its international PR and IR activities surrounding the announcement, which saw the value of BerGenBio’s shares rise more than 100% on the day of the news. 

BerGenBio intends to use the net proceeds from the Private Placement to take full advantage of clinical development opportunities stemming from its technology and to progress readiness for early commercialisation possibilities, as well as for general corporate purposes.

“We are delighted to have supported BerGenBio on their strategic communications through their ACCORD trial participation and the successful private placement. The potential of the science has been underlined by the request to test bemcentinib in the ACCORD study and we look forward to continuing to work closely with the team as they progress their whole pipeline.”

Mary-Jane Elliott

Managing Partner of Consilium Strategic Communications

“We are grateful for the support and guidance provided by the Consilium team throughout this exciting and busy time. The team has worked with us to great effect, helping us communicate the BerGenBio story to a wide group of stakeholders and securing significant, impactful international media attention.”

Richard Godfrey

Chief Executive Officer at BerGenBio

The Consilium team representing BerGenBio ASA comprises Mary-Jane Elliott, Chris Welsh, Carina Jurs, Lucy Featherstone and Maya Bennison

BerGenBio’s announcement can be viewed in full here.



For more information, please contact:


Consilium Strategic Communications

Mary-Jane Elliott / Amber Fennell

Tel: +44(0)20 3709 5700



Follow us: @consiliumhc


About Consilium Strategic Communications

Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.


About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. 

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com


Back to previous page